IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine, for use in Phase 2/3 clinical trials by the University of Oxford

Read full release

IRBM signs agreement with MD Anderson Cancer Center to generate novel immune-checkpoint monoclonal antibodies.

Read full release

CHDI Foundation extends collaboration with IRBM to accelerate development of Huntington’s disease therapeutics

Read full release